For HIV patients with belly fat who responded to tesamorelin, denser subcutaneous fat (on CT scans) was linked to less subcutaneous fat area, showing that fat quality and quantity are related.

In HIV patients with belly fat who responded to tesamorelin, thicker subcutaneous fat (on CT scans) was linked to higher adiponectin levels, which is beneficial for metabolic health.

In HIV patients with belly fat who responded to tesamorelin, denser visceral fat (on CT scans) was associated with less visceral fat area, showing that fat quality and quantity are related.

Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher levels of the metabolism-regulating hormone adiponectin, suggesting improved fat function.

For HIV patients with belly fat who responded to tesamorelin, higher subcutaneous fat density (on CT scans) was linked to lower total cholesterol levels, which is good for heart health.

When HIV patients with belly fat responded to tesamorelin, thicker visceral fat (as seen on CT scans) was linked to higher levels of adiponectin, a hormone that helps regulate metabolism.